Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis + lactobacillus plantarum
- Development stage
- Unknown
- Lead developer
- Chengdu Women’s and Children’s Central Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
bifidobacterium animalis + lactobacillus plantarum is a probiotic combination therapy being evaluated for the prevention and treatment of recurrent respiratory tract infections (RRTI), particularly in pediatric populations. Developed in clinical research settings such as Chengdu Women and Children's Central Hospital, this microbial therapy functions via the gut-lung axis to enhance the host's immune defense. The mechanism of action involves the modulation of intestinal microbiota, which in turn stimulates the production of secretory immunoglobulin A (sIgA) and regulates the balance of Th1 and Th2 cytokines. By strengthening the mucosal barrier and promoting a robust systemic immune response, the combination aims to reduce the incidence, duration, and severity of respiratory infections.
- Other names
- Bifidobacterium animalis subsp. lactis + Lactobacillus plantarum
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on bifidobacterium animalis + lactobacillus plantarum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis + lactobacillus plantarum.